US Stocks Movement | ARS Pharmaceuticals plummets 21% pre-market as it fails to secure new payer coverage and lowers full-year expense guidance

Golden Ten Data June 25｜ARS Pharmaceuticals dropped 21.5% pre-market to $8.27. The main driver is that neffy failed to secure expanded commercial coverage in the July 1st insurance update cycle, combined with a downward revision of annual spending guidance. However, some analysts believe the market has overreacted — the coverage expansion is only delayed, cost discipline is strengthened, the 2027 breakeven target remains unchanged, and there is a potential CSU data catalyst in Q4.